Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP
J Natl Cancer Inst. 2007 99 (11): 838-46

PMID: 17551144 · DOI:10.1093/jnci/djk195

MeSH Terms (20)

Adult Aged Aged, 80 and over Algorithms Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung ErbB Receptors Female Gefitinib Humans Lung Neoplasms Male Middle Aged Prognosis Protein Kinase Inhibitors Proteomics Quinazolines Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Survival Rate Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: